Clinical Trial Update: Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) [Phase 1, Phase 2]

View source ↗

Summary

Rigel Pharmaceuticals is conducting a Phase 1/2 study of the investigational agent R289 in adults with low-risk myelodysplastic syndrome, and the trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• R289

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Low Risk Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: RECRUITING